ClinicalTrials.gg
Active, not recruitingNCT06832618TRuE-AD5Updated Aug 19, 2026

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

A Phase 3 interventional study of Ruxolitinib and Vehicle Cream in Atopic Dermatitis, sponsored by Incyte Corporation. Active, not recruiting at 93 sites in 10 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing ruxolitinib in Dermatitis, Atopic — 2 open to participants now, 3 under way, 1 of them phase 3. ruxolitinib · Dermatitis, Atopic.

Enrollment
6th of 15
159 · median 77
Started
2025
the only one that year
Phase 3
6 of 15
none open now
Registered
13th of 15
by date
Lead sponsor
13 of 15
Incyte Corporation

Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, this one is the 6th largest by enrollment, is the only one that started in 2025, is one of 6 in phase 3, and was the 13th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 15 studies testing ruxolitinib in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ruxolitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to \<18 Years Old) with moderate atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Atopic Dermatitis
  • Ruxolitinib
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 6 to \< 18 years at the VC Day 1 visit.
  • Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria.
  • AD duration of at least 3 months for 6 to 11 year olds and at least 2 years for 12 to \< 18 year olds (participant/parent/guardian may verbally report signs and symptoms of AD).
  • EASI score > 7 at the screening and VC Day 1 visits.
  • IGA score of 3 at the screening and VC Day 1 visits.
  • Percent BSA (excluding the scalp) with AD involvement of at least 3% and up to 20% at the screening and VC Day 1 visits.
  • Itch NRS or WI NRS score ≥ 4 at the screening and VC Day 1 visits, defined as the average of the 7 days directly before the VC/Day 1 visit, with Itch NRS or WI NRS values available for at least 4 of the 7 days.
  • Documented recent history (within 12 months before the screening visit) of inadequate response, intolerance, or to TCSs and TCIs as follows:

    • Inadequate response:

      • For TCSs: Inability of a given TCS to induce and maintain remission or to contain the AD severity at an acceptable level (comparable to an IGA score of 0 [clear] or 1 [almost clear]) despite treatment for 28 days or for the maximum duration recommended by the product prescribing information (eg, 14 days for superpotent TCSs), whichever is shorter and
      • For TCIs: Inability of a given TCI to induce and maintain remission or to contain the AD severity at an acceptable level (comparable to an IGA score of 0 [clear] or 1 [almost clear]) despite treatment according to the product prescribing information.

Note: Documented (within 12 months before the screening visit) systemic treatment for AD (eg, oral , cyclosporine, methotrexate, azathioprine, mycophenolate mofetil) or phototherapy or photo(chemo)therapy can also be considered as a surrogate for inadequate response to TCSs and TCIs.

  • Intolerance: side effects, safety risks, or skin tolerability issues that outweigh the potential treatment benefits and are the reason why a topical treatment could not be restarted or continued.

Note: Documented history (more than 12 months prior to the screening visit) of clinically significant adverse reactions with use of TCSs and/or TCIs that in the opinion of the investigator outweigh the benefits of restarting treatment would also be considered as evidence of intolerance.

  • Contraindication: As defined in the product prescribing information.
  • Agreement by participants and guardians to discontinue all agents used by the participant to treat AD from the screening visit through the final safety follow-up visit, except as outlined in the protocol.
  • For sexually active participants, willingness to take appropriate measures to avoid pregnancy or fathering a child for the duration of study participation with the exception of prepubescent participants.

Note: Female participants who have reached menarche must have a negative urine pregnancy test at the screening and baseline visits before the first application of study cream at baseline. They must also take appropriate precautions to avoid pregnancy from the screening visit through the safety follow-up visit.

- Ability to comprehend and willingness to sign an ICF or written of the parent(s) or legal guardian and a verbal or written assent from the participant when possible.

Note: A signed written ICF must be obtained for inclusion; see protocol.

Exclusion criteria

Exclusion Criteria:

  • Unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the investigator in the 4 weeks prior to the VC Day 1 visit.
  • Concurrent conditions and history of other diseases as follows:

    • (eg, lymphoma, acquired immunodeficiency syndrome, Wiskott-Aldrich syndrome).
    • Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the VC Day 1 visit.
    • Active acute bacterial, fungal, or viral skin infection (eg, herpes simplex, herpes zoster, chickenpox) within 1 week before the VC Day 1 visit.
    • Any other concomitant skin disorder (eg, generalized erythroderma, such as Netherton syndrome), pigmentation, or extensive scarring that, in the opinion of the investigator, may interfere with the evaluation of AD lesions or compromise participant safety.
    • Presence of AD lesions only on the hands or feet without prior history of involvement of other classic areas of involvement such as the face or the flexural folds.
    • Other types of eczema within the 6 months prior to screening. Note: Seborrheic dermatitis on the scalp is allowed, as the scalp will not be treated with study cream.
    • Current or history of or C virus infection.
  • Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, including administration of study cream and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • Any of the following clinical laboratory test results at screening:

    • \< 10 g/dL.
    • Liver function tests:

      • \< 1000/μL.
      • count \< 100,000/μL.
      • or ALT ≥ 2 × .
      • Alkaline phosphatase > 1.5 × ULN.
      • > 1.5 × ULN (isolated bilirubin > 1.5 × ULN is acceptable if bilirubin isfractionated and direct bilirubin \< 35%) with the exception of Gilbert disease.
    • Estimated \< 30 mL/min/1.73 m2 (using the Modification of Diet in Renal Disease equation).
    • Positive serology test results for antibody.
    • Any other laboratory result that, in the opinion of the investigator, poses a significant risk to the participant.
  • Use of any of the following treatments within the indicated before the VC Day 1 visit:

    • 5 half-lives or 12 weeks, whichever is longer: biologic agents. For biologic agents with washout periods longer than 12 weeks (eg, rituximab), consult the medical monitor.
    • 4 weeks: systemic or adrenocorticotropic hormone analogs, cyclosporine, methotrexate, azathioprine, or other systemic immunosuppressive (eg, JAK inhibitors) or immunomodulating (eg, mycophenolate or tacrolimus) agents.
    • 2 weeks or 5 half-lives, whichever is longer: strong systemic inhibitors.
    • 2 weeks: immunizations with ; sedating antihistamines unless on a long-term stable regimen (nonsedating antihistamines are permitted).

Note: COVID-19 vaccination is allowed.

  • 1 week: use of other topical treatments for AD, other than bland emollients (eg, Aveeno® creams, ointments, sprays, soap substitutes), such as antipruritics (eg, doxepin cream), corticosteroids, calcineurin inhibitors, PDE4 inhibitors, coal tar (shampoo), antibiotics, or antibacterial cleansing body wash/soap.

Note: Diluted sodium hypochlorite "bleach" baths are allowed as long as they do not exceed 2 baths per week and their frequency remains the same throughout the study.

  • History of treatment failure with any systemic or topical JAK inhibitor (eg, ruxolitinib, tofacitinib, baricitinib, abrocitinib, upadacitinib) for AD or any other inflammatory condition.
  • Ultraviolet light therapy or prolonged exposure to natural or artificial sources of UV radiation (eg, sunlight or tanning booth) within 2 weeks prior to the baseline visit and/or intention to have such exposure during the study that is thought by the investigator to potentially impact the participant's AD.
  • Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before baseline with another medication or current enrollment in another investigational drug Protocol.
  • Pregnant or lactating participants or those considering pregnancy during the period of their study participation.
  • Living with anyone participating in any current Incyte-sponsored ruxolitinib cream study.
  • Known allergy or reaction to any component of the study cream formulation.
  • In the opinion of the investigator, unable or unlikely to comply with the administration schedule, study evaluations, and procedures (eg, eDiary compliance).
  • Committed to a mental health institution by virtue of an order issued either by the judicial or the administrative authorities.
  • Employees of the sponsor, sponsor delegates (eg, contract research organizations), or investigators or are otherwise dependents of them.
  • The following participants are excluded in France: vulnerable populations according to article L.1121-6 of the French Public Health Code and adults under legal protection, or who are unable to express their consent per article L.1121-8 of the French Public Health Code, not affiliated to a social security per article L.1121-8-1 of the French Public Health Code.
  • In the EU, participants considered incapacitated (according to CTR Article 31).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
159 participants (actual)

Study arms

  • Experimental
    Vehicle-controlled (VC) Period: Ruxolitinib (1.5% Cream)

    Study drug will be administered twice daily.

    Drug: Ruxolitinib

  • Placebo comparator
    VC Period: Vehicle Cream

    Matching vehicle cream will be administered twice daily.

    Drug: Vehicle Cream

  • Experimental
    Disease Control (DC) Period: Ruxolitinib (1.5% Cream)

    Study drug will be administered twice weekly.

    Drug: Ruxolitinib

  • Placebo comparator
    DC Period: Vehicle Cream

    Matching vehicle cream will be administered twice weekly.

    Drug: Vehicle Cream

  • Experimental
    DC Period: Open Label - Ruxolitinib (1.5% Cream)

    Study drug will be administered twice daily to treat Disease Exacerbations.

    Drug: Ruxolitinib

  • Experimental
    Open-label Extension (OLE) period: Ruxolitinib (1.5% Cream)

    Study drug will be administered twice daily.

    Drug: Ruxolitinib

Interventions

  • The study cream will be applied topically as defined in the protocol for each period.

    Also known as: Opzelura

  • DrugVehicle Cream

    Matching vehicle cream will be applied topically as defined in the protocol for each period.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. VC Period: Binary response status of Eczema Area and Severity Index 75 (EASI75)

    Defined as achieving ≥ 75% improvement in Eczema Area and Severity Index (EASI) score from baseline.

    Time frame: VC Week 8

Secondary outcomes

  1. VC Period: Binary response status of Investigator's Global Assessment Treatment Success (IGA-TS)

    Defined as achieving Investigator's Global Assessment (IGA) score of 0 or 1 with ≥ 2-grade improvement from baseline.

    Time frame: VC Week 8

  2. VC Period: Binary response status of ≥ 4-point improvement in Itch Numeric Rating Scale (NRS) score (ITCH4)

    Defined as achieving ≥ 4-point improvement in Itch NRS \[participants aged 12 to \< 18 years\] or Worst Itch Numerical Rating Scale (WI NRS) \[participants aged 6 to \< 12 years\] score from baseline.

    Time frame: VC Week 8

  3. DC Period: Time to first disease exacerbation, defined as Investigator's Global Assessment score of ≥ 2 (DE) in the DC period

    Defined as responders \[IGA score \< 2\] from the VC period or the OLE period rerandomized to proactive treatment, time to first DE, where DE is defined as IGA score of ≥ 2.)

    Time frame: Up to 44 Weeks

  4. Number of Treatment Emergent Adverse Events (TEAEs)

    Defined as any AE reported for the first time or worsening of a pre-existing event after the first application of study cream.

    Time frame: From Baseline up to 70 weeks

  5. Binary response status of Eczema Area and Severity Index 75 (EASI75) at each postbaseline visit except Week 8

    Defined as achieving ≥ 75% improvement in Eczema Area and Severity Index (EASI) score from baseline.

    Time frame: Up to 44 weeks

  6. Binary response status of Investigator's Global Assessment Treatment Success (IGA-TS) at each postbaeline visit except Week 8

    Defined as achieving Investigator's Global Assessment (IGA) score of 0 or 1 with ≥ 2-grade improvement from baseline.

    Time frame: Up to 44 weeks

  7. Binary response status of ≥ 4-point improvement in Itch Numeric Rating Scale (NRS) score (ITCH4)

    Defined as achieving ≥ 4-point improvement in Itch NRS \[participants aged 12 to \< 18 years\] or Worst Itch Numerical Rating Scale (WI NRS) \[participants aged 6 to \< 12 years\] score from baseline.

    Time frame: Days 2, 3, and 7 and VC Weeks 2 and 4

  8. VC Period: Time to achieve ITCH4

    Defined as time to achieve ≥ 4-point improvement in Itch NRS \[participants aged 12 to \< 18 years\] or Worst Itch Numerical Rating Scale (WI NRS) \[participants aged 6 to \< 12 years\] score from baseline.

    Time frame: Up to 8 weeks

  9. VC Period: Binary response status of both EASI75 and IGA-TS at each postbaseline visit in the VC period

    Time frame: Up to 44 weeks

  10. VC Period: The binary response status of DLQI-4/CDLQI-4 at VC Weeks 2, 4, and 8

    Dermatology Life Quality Index (DLQI)-4/ Children's Dermatology Life Quality Index (CDLQI)-4 is defined as achieving ≥ 4-point improvement in DLQI/CDLQI from baseline.

    Time frame: Weeks 2, 4 and 8

  11. VC Period and DC Period: Change from baseline in the CDLQI (or DLQI) score at each postbaseline visit

    The DLQI will be administered to participants aged 16 and 17 years. The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. The CDLQI will be administered to participants aged 6 to 15 years. The CDLQI is a simple validated questionnaire to measure how much the skin problem has affected the participant over the past week (7-day recall). The higher the score, the more quality of life is impaired.

    Time frame: Up to 52 weeks

  12. VC Period and DC Period: Change from baseline in the Patient-Oriented Eczema Measure (POEM) score at each postbaseline visit

    The POEM is a 7-question quality-of-life assessment that asks how many days the participant has been bothered by various aspects of their skin condition during the past 7 days. A negative change from Baseline indicates improvement.

    Time frame: Up to 52 weeks

  13. VC Period and DC Period: Acceptability and tolerability assessment (exit interview/questionnaire)

    The overall impression of the acceptability and tolerability of study cream will be assessed quantitatively using the Pediatric Impression of Cream Acceptability and Tolerability questionnaire. This is a structured questionnaire with 2 questions: one for assessing overall impression of acceptability and one for assessing tolerability. Each question has 4 possible response options, with a corresponding score from 1 to 4. The total score will range from 2 (most acceptable and tolerable) to 8 (least acceptable and tolerable).

    Time frame: VC Period Week 8 and DC Period Week 44

  14. DC Period: Number of disease exacerbations (DEs)

    Defined as Investigator's Global Assessment score of ≥ 2.

    Time frame: Up to 44 weeks

  15. DC Period: Amount of ruxolitinib cream used

    Time frame: Up to 44 weeks

  16. VC Period: Plasma concentrations of ruxolitinib and PK parameters (Ctrough,ss)

    Trough and steady-state concentrations for ruxolitinib in plasma will be determined.

    Time frame: VC Week 2 and VC Week 8

07

Study locations

93 sites
08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Aug 2026, 13 months.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 13 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2025
First posted
Feb 18, 2025
StartActual
Jun 17, 2025
Primary completionActual
Aug 7, 2026
CompletionEst.
Sep 6, 2027
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06832618
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Feb 18, 2025
Start date
Jun 17, 2025
Primary completion
Aug 7, 2026
Completion
Sep 6, 2027 (estimated)
Last update
Aug 19, 2026

Study contacts

Incyte Medical Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion